These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20665889)

  • 1. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?
    Mihu CN; Kassis C; Ramos ER; Jiang Y; Hachem RY; Raad II
    Cancer; 2010 Nov; 116(22):5290-6. PubMed ID: 20665889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis.
    Kontoyiannis DP; Boktour M; Hanna H; Torres HA; Hachem R; Raad II
    Cancer; 2005 Jun; 103(11):2334-7. PubMed ID: 15844093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial).
    Caillot D; Thiébaut A; Herbrecht R; de Botton S; Pigneux A; Bernard F; Larché J; Monchecourt F; Alfandari S; Mahi L
    Cancer; 2007 Dec; 110(12):2740-6. PubMed ID: 17941026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard dosing regimen of liposomal amphotericin B is as effective as a high-loading dose for patients with invasive aspergillosis: AmBiLoad trial.
    Lass-Flörl C
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):929-32. PubMed ID: 18039077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy.
    Lionakis MS; Lewis RE; Chamilos G; Kontoyiannis DP
    Pharmacotherapy; 2005 Sep; 25(9):1174-80. PubMed ID: 16164392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin.
    Graybill JR; Bocanegra R; Gonzalez GM; Najvar LK
    J Antimicrob Chemother; 2003 Oct; 52(4):656-62. PubMed ID: 12972452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.
    Steinbach WJ; Stevens DA; Denning DW
    Clin Infect Dis; 2003 Oct; 37 Suppl 3():S188-224. PubMed ID: 12975752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections.
    Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K
    Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in combination therapy for invasive aspergillosis].
    Luo L; Tong Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2014 Jan; 37(1):41-4. PubMed ID: 24694973
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis.
    Kirkpatrick WR; Vallor AC; McAtee RK; Ryder NS; Fothergill AW; Rinaldi MG; Patterson TF
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4751-3. PubMed ID: 16251321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Invasive Aspergillosis in Hematological Patients].
    Kimura S
    Med Mycol J; 2016; 57(2):J77-88. PubMed ID: 27251320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
    Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
    Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of micafungin for treatment of serious Candida infections in patients with or without malignant disease.
    Cornely OA; Marty FM; Stucker F; Pappas PG; Ullmann AJ
    Mycoses; 2011 Nov; 54(6):e838-47. PubMed ID: 21668522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.
    Kartsonis NA; Saah AJ; Joy Lipka C; Taylor AF; Sable CA
    J Infect; 2005 Apr; 50(3):196-205. PubMed ID: 15780413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis.
    Kirkpatrick WR; Coco BJ; Patterson TF
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1567-9. PubMed ID: 16569887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
    Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
    Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
    Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.